Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a minor animal health segment included in reporting. The company focuses on therapeutic areas including neurosciences, endocrinology, oncology, and cardiovascular health.
Key Financial Metrics
| Metric (in millions) | Q3 2004 | Q3 2003 | 9 Months 2004 | 9 Months 2003 |
|---|---|---|---|---|
| Net Sales | $3,280.4 | $3,139.4 | $10,213.6 | $9,117.0 |
| Net Income | $755.2 | $714.4 | $1,812.5 | $1,813.6 |
| Earnings Per Share (Diluted) | $0.69 | $0.66 | $1.66 | $1.68 |
| Gross Margin % | 75.3% | 78.4% | 76.9% | 78.7% |
| Operating Cash Flow (9 Mo) | $2,321.1 (2004) vs $2,480.1 (2003) | |||
| Total Debt | $6.18 billion (Sep 30, 2004) | |||
| Cash & Short-term Investments | $4.17 billion (Sep 30, 2004) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4% in Q3 2004 and 12% for the nine-month period compared to 2003. International sales grew 17% year-to-date, outpacing U.S. growth of 8%.
- Profitability: Q3 net income rose 6% to $755.2 million. However, nine-month net income remained flat at $1.81 billion due to significant non-recurring charges.
- Special Charges:
- Q1 2004: $362.3 million charge for acquired in-process research and development (IPR&D) related to the Applied Molecular Evolution (AME) acquisition.
- Q2 2004: $108.9 million in asset impairment charges related to manufacturing and R&D strategy reviews.
- Product Performance:
- Zyprexa: U.S. sales declined 22% in Q3 due to competitive pressure and wholesaler destocking; international sales grew 12%.
- Strattera: Sales surged 51% in Q3 to $163.6 million.
- Gemzar: Sales increased 25% in Q3 driven by new indications and prior-year destocking effects.
- Cymbalta: Launched in late August 2004, generating $32.5 million in Q3 sales.
- Debt & Liquidity: Total debt increased by $1.29 billion to $6.18 billion, primarily due to commercial paper issuances and a $1.0 billion floating rate note issuance in August 2004 to fund operations and refinance existing debt.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2004 Full Year Guidance:
- EPS: Expected range of $2.13 to $2.20 (includes estimated Q4 restructuring charges of $0.21–$0.26 per share).
- Sales Growth: Expected 9% to 10% for the full year.
- Expenses: R&D expected to grow in the mid-teens; Marketing and Admin expected to grow in low single digits.
- Restructuring: In October 2004, the company announced a restructuring plan involving nearly 1,000 U.S. position eliminations, closure of the RTP Laboratory site, and narrowing of the Clinton, Indiana manufacturing site. Total estimated costs are $320–$420 million (pretax), with $250–$320 million in non-cash charges, substantially all to be reported in Q4 2004.
- Tax Legislation: The American Jobs Creation Act of 2004 may result in a temporary increase in the effective tax rate in Q4 2004 due to the repatriation of approximately $8.0 billion in overseas earnings.
Risks and Contingencies
- Zyprexa Patent Litigation: Three generic manufacturers (Zenith, Reddy, Teva) have challenged U.S. patents expiring in 2011. A trial concluded in early 2004; the company is awaiting a decision. An unfavorable outcome could materially adversely impact results.
- Government Investigations: The U.S. Department of Justice and the U.S. Attorney for the Eastern District of Pennsylvania are investigating marketing and promotional practices regarding Evista, Prozac, and Zyprexa. Potential outcomes include fines, penalties, or criminal charges.
- Product Liability: Approximately 125 product liability cases involving ~340 claimants allege Zyprexa caused diabetes or high blood-glucose levels. Two nationwide class actions were filed but personal injury claims were dismissed in exchange for tolling agreements; medical monitoring claims remain.
- Evista Patent Litigation: Barr Laboratories has challenged patents expiring 2012–2017. Trial is scheduled for February 2006.
Investor Verification Checklist
- Zyprexa Patent Ruling: Monitor the court decision regarding the generic patent challenges, as this poses the most significant near-term revenue risk.
- Q4 Restructuring Impact: Verify the actual costs and timing of the announced $320–$420 million restructuring charges in the Q4 2004 filing.
- Tax Accruals: Confirm the specific tax impact of the American Jobs Creation Act repatriation in the Q4 2004 results.
- Government Investigation Status: Track developments in the DOJ and U.S. Attorney investigations regarding marketing practices for potential fines or settlements.
- New Product Launches: Assess the commercial uptake of Cymbalta and Alimta following their recent launches and approvals.